Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904600 | 0.81 | SYK (0.57) | ATMCTSBSYKCTSLCTSS | |
| SCHEMBL14768567 | 0.81 | SYK (0.57) | ATMCTSBSYKCTSLCTSS | |
| SCHEMBL4784830 | 0.80 | ELANE (0.49) | ALDH1A1ATMCTSBSYKELANE | |
| SCHEMBL25076347 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AATMCTSB | |
| SCHEMBL10421523 | 0.79 | TACR1 (0.43) | ALDH1A1MEN1KMT2AATMCTSL | |
| SCHEMBL10420285 | 0.79 | TACR1 (0.43) | ALDH1A1MEN1KMT2AATMCTSL | |
| SCHEMBL10051908 | 0.78 | CTSB (0.46) | ATMCTSBELANEPOLBCTSK | |
| SCHEMBL7770306 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KMT2ACTSBSYKELANE | |
| SCHEMBL8667196 | 0.77 | TRPM8 (0.54) | ALDH1A1ATMCTSBSYKELANE | |
| SCHEMBL10420029 | 0.77 | TACR1 (0.41) | ALDH1A1MEN1KMT2AATMELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004065334-A1 | METHOD OF REMOVING ORGANOTIN RESIDUE | CHIROGEN PTY LIMITED (AU) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004065335-A1 | ENANTIOSELECTIVE REDUCTION METHOD | CHIROGEN PTY LIMITED (AU) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004031198-A1 | ENANTIOSELECTIVE REDUCTIVE METHODS USING CHIRAL ORGANOSTANNANES | CHIROGEN PTY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004018487-A1 | CHIRAL ORGANOSILICON HYDRIDES | CHIROGEN PTY LIMITED (AU) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004011473-A1 | ORGANOGERMANIUM COMPOUNDS AND METHODS FOR THEIR USE | CHIROGEN PTY LIMITED (AU) | 2004-02-05 | — | — | WO | disclosed |
| US-20030166979-A1 | Catalytic reduction using hydrogen | DAKTERNIEKS DAINIS (AU) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166979-A1 | Catalytic reduction using hydrogen | GRHPR, CBR1, SPR | ALDH1A1 141/4885MEN1 1920/4885KMT2A 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.